Literature DB >> 27328814

Kinetics of calcium oxalate crystal formation in urine.

Norbert Laube1, Florian Klein2, Falk Bernsmann3.   

Abstract

It is routinely observed that persons with increased urinary stone risk factors do not necessarily form uroliths. Furthermore, stone formers can present with urinalyses that do not reflect the clinical picture. We explain this discrepancy by differences in crystallization kinetics. In 1162 urines, crystallization of Ca-oxalate was induced according to the BONN-Risk-Index (BRI) method. The urine's relative light transmissivity (RLT) was recorded from 100 % at start of titration to 95 % due to nuclei formation and crystal growth. From the RLT changes, a measure of the thermodynamic inhibition threshold of crystal formation (BRI) and of crystal growth kinetics is derived ("turbidity slope" after crystallization onset). On average, subjects presenting with a low inhibition threshold, i.e., high BRI, also present significantly higher crystal growth rates compared with subjects in lower BRI classes. Only subjects in the highest BRI class show a lower growth rate than expected, probably due to a depletion of supersaturation by massive initial nucleation. With increasing thermodynamic risk of crystal formation (i.e., increasing BRI) due to an imbalance between inhibitors and promoters of crystal formation, an increase in the imbalance between inhibitors and promoters of crystal growth (i.e., increasing growth rate) is observed. Both lead to an increased urolith formation risk. Healthy subjects with increased BRI are an exception to this trend: their urine is thermodynamically prone to form stones, but they show a kinetic inhibition preventing nuclei from significant growth.

Entities:  

Keywords:  BONN Risk Index; Induced crystallization; Thermodynamic inhibition; Urolithiasis supersaturation

Mesh:

Substances:

Year:  2016        PMID: 27328814     DOI: 10.1007/s00240-016-0900-y

Source DB:  PubMed          Journal:  Urolithiasis        ISSN: 2194-7228            Impact factor:   3.436


  38 in total

1.  Synergism between urinary prothrombin fragment 1 and urine: a comparison of inhibitory activities in stone-prone and stone-free population groups.

Authors:  Dawn Webber; Allen L Rodgers; Edward D Sturrock
Journal:  Clin Chem Lab Med       Date:  2002-09       Impact factor: 3.694

Review 2.  Protein inhibitors of crystallization.

Authors:  F I Coe; J H Parks; Y Nakagawa
Journal:  Semin Nephrol       Date:  1991-03       Impact factor: 5.299

3.  Stone composition as a function of age and sex.

Authors:  John C Lieske; Andrew D Rule; Amy E Krambeck; James C Williams; Eric J Bergstralh; Ramila A Mehta; Thomas P Moyer
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-02       Impact factor: 8.237

4.  Epidemiology of urolithiasis: an update.

Authors:  Alberto Trinchieri
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

5.  Urinary pyrophosphate in patients with recurrent calcium urolithiasis and in healthy controls: a re-evaluation.

Authors:  P O Schwille; G Rümenapf; G Wölfel; R Köhler
Journal:  J Urol       Date:  1988-08       Impact factor: 7.450

6.  Can the Bonn Risk Index be replaced by a simple measurement of the urinary concentration of free calcium ions?

Authors:  Norbert Laube; Stefan Hergarten
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

7.  Evidence that calgranulin is produced by kidney cells and is an inhibitor of calcium oxalate crystallization.

Authors:  S N Pillay; J R Asplin; F L Coe
Journal:  Am J Physiol       Date:  1998-08

8.  Relevance of the BONN Risk Index for metabolic monitoring of patients with calcium oxalate urolithiasis: a clinical application study of the Urolizer.

Authors:  Wolfgang Berg; Robin Bechler; Claudia Haas; Norbert Laube
Journal:  Urol Res       Date:  2009-02-10

9.  An update on metabolic assessment in patients with urinary lithiasis.

Authors:  Carmen Regina Petean Ruiz Amaro; Jose Goldberg; Patricia Capuzzo Damasio; Victor Augusto Leitão; Benjamin Turney; Carlos Roberto Padovani; João Luiz Amaro
Journal:  World J Urol       Date:  2014-03-13       Impact factor: 4.226

10.  Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules.

Authors:  Jeffrey A Wesson; Richard J Johnson; Marrilda Mazzali; Anne M Beshensky; Susan Stietz; Ceci Giachelli; Lucy Liaw; Charles E Alpers; William G Couser; Jack G Kleinman; Jeremy Hughes
Journal:  J Am Soc Nephrol       Date:  2003-01       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.